Genmab A (GMAB) EBIT Margin (2018 - 2026)
Genmab A (GMAB) reported EBIT Margin of 20.09% for Q1 2026, down 620.0% on a YoY basis from 3.86% in Q1 2025, and down 55.27% quarter-over-quarter from 44.91% in Q3 2025.
Genmab A (GMAB) EBIT Margin (2018 - 2026) Analysis & Trends
Genmab A has reported EBIT Margin for 6 years, with the latest figure at 20.09% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 620.0% year-over-year to 20.09%; the trailing twelve-month figure through Mar 2026 stood at 33.36% (up 418.0% YoY), and the FY2025 full-year result was 28.63%, down 251.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 20.09%, down from 44.91% in the prior quarter.
- The five-year high for EBIT Margin was 44.91% in Q3 2025, with the low at 19.24% in Q1 2024.
- Historically, EBIT Margin has averaged 31.11% across 3 years, with a median of 30.3% in 2024.
- Annual changes were most pronounced in 2025 — EBIT Margin jumped 862 bps — and 2026, when it sank 620 bps.
- Genmab A's EBIT Margin stood at 37.99% in 2024, then advanced by 18 bps to 44.91% in 2025, then slumped by 55 bps to 20.09% in 2026.
- The last three EBIT Margin figures came in at 20.09% (Q1 2026), 44.91% (Q3 2025), and 38.92% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 20.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.09% |
| Sep 30, 2025 | 44.91% |
| Jun 30, 2025 | 38.92% |
| Mar 31, 2025 | 26.29% |
| Sep 30, 2024 | 37.99% |
| Jun 30, 2024 | 30.30% |
| Mar 31, 2024 | 19.24% |
| Sep 30, 2020 | 49,767,981.44% |
| Dec 31, 2019 | 33.75% |
| Sep 30, 2019 | 0.00% |
| Dec 31, 2018 | 33.44% |